ARK Genomic Revolution ETF
ARKG ThematischAktualisiert: Apr 6, 2026, 12:07 UTC
Kennzahlen
Top 10 Holdings
| Position | Ticker | Gewichtung | Anteil |
|---|---|---|---|
| CRISPR Therapeutics AG | CRSP | 9.96% | |
| Tempus AI Inc Class A common stock | TEM | 8.26% | |
| Twist Bioscience Corp | TWST | 7.88% | |
| 10x Genomics Inc Ordinary Shares - Class A | TXG | 6.06% | |
| Personalis Inc | PSNL | 6.03% | |
| Beam Therapeutics Inc | BEAM | 5.12% | |
| Illumina Inc | ILMN | 4.27% | |
| Guardant Health Inc | GH | 4.16% | |
| Natera Inc | NTRA | 3.93% | |
| Recursion Pharmaceuticals Inc Class A | RXRX | 3.73% |
Sektor-Gewichtung
Über diesen ETF
Der ARK Genomic Revolution ETF (ARKG) ist ein Thematisch ETF mit einer Kostenquote (TER) von 0.75% und einem Fondsvolumen von $1.3B., wobei die größten Positionen CRISPR Therapeutics AG, Tempus AI Inc Class A common stock, Twist Bioscience Corp sind. Seit Jahresbeginn hat der ARKG eine Rendite von -6.24% erzielt.
The fund is an actively-managed exchange-traded fund ("ETF") that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the fund's investment theme of the genomics revolution ("Genomics Revolution Companies"). It is non-diversified.
Wo kann ich ARKG kaufen?
Vergleiche die besten Broker für ETF-Sparpläne — niedrige Gebühren, seriöse Anbieter, reguliert.